Showing results (21-30 of 45) with videos related to
Sort By:
Pageof 5
Lung Cancer (Amsterdam, Netherlands)|November 6, 2021
In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trialAkira Hamada, Kenichi Suda, Takamasa Koga, et al.Surgery Today|February 2, 2019
Life-threatening complications after pulmonary resection for lung cancer in patients on chronic hemodialysisKenji Tomizawa, Katsuaki Sato, Shuta Ohara, et al.Surgery Today|February 21, 2021
The prevalence and risk factors associated with preoperative deep venous thrombosis in lung cancer surgeryToshiki Takemoto, Junichi Soh, Shuta Ohara, et al.Translational Lung Cancer Research|November 19, 2020
Prognostic implications of preoperative versus postoperative circulating tumor DNA in surgically resected lung cancer patients: a pilot studyShuta Ohara, Kenichi Suda, Kazuko Sakai, et al.Lung Cancer (Amsterdam, Netherlands)|December 2, 2017
Clinical significance of tumor cavitation in surgically resected early-stage primary lung cancerKenji Tomizawa, Shigeki Shimizu, Shuta Ohara, et al.Surgery Today|May 16, 2020
Prognostic value of plasma fibrinogen and D-dimer levels in patients with surgically resected non-small cell lung cancerShuta Ohara, Kenichi Suda, Kenji Tomizawa, et al.Cells|September 13, 2025
Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations-An In Vitro StudyHana Oiki, Kenichi Suda, Akira Hamada, et al.Cancer Research Communications|November 19, 2025
Low OLFM1 and BMP6 Expression Predicts Recurrence in Early-Stage Nonsquamous NSCLC with Pure Solid Tumor AppearanceKenichi Suda, Yukihiro Yoshida, Hidenori Sato, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 10, 2021
KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro ExperimentsTakamasa Koga, Kenichi Suda, Toshio Fujino, et al.JTO Clinical and Research Reports|May 16, 2022
Presence of a Ground-Glass Opacity Component Is the True Prognostic Determinant in Clinical Stage I NSCLCAkira Hamada, Kenichi Suda, Toshio Fujino, et al.Pageof 5